secwatch / observer

8-K filed May 28, 2026, 3:01 PM ET CIK 0002133003

other material confidence high sentiment neutral materiality 0.70

Wells Fargo Commercial Mortgage Trust 2026-5C9 issues $512.996M in certificates

Wells Fargo Commercial Mortgage Trust 2026-5C9

Issued $512,996,000 aggregate principal amount of Publicly Offered Certificates on May 28, 2026.
Net proceeds to registrant after expenses approximately $546,721,030.
Certificates backed by 29 fixed-rate mortgage loans on 138 commercial/multifamily properties.
RREF V-D Direct Lending Investments retains 5.0% fair value eligible horizontal residual interest and 2.07% vertical interest for credit risk retention.
Underwriters include Wells Fargo Securities, J.P. Morgan Securities, SG Americas, Goldman Sachs, Academy Securities, Drexel Hamilton, Natixis Securities, Barclays Capital, and Siebert.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001539497-26-001612
form_type: 8-K
ticker: null
cik: 0002133003
company_name: Wells Fargo Commercial Mortgage Trust 2026-5C9
filed_at: 2026-05-28T19:01:04+00:00
discovered_at: 2026-05-28T19:02:00.566482+00:00
generated_at: 2026-05-28T19:03:15.781254+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001539497-26-001612
json_url: https://secwatch.observer/filing/0001539497-26-001612.json
markdown_url: https://secwatch.observer/filing/0001539497-26-001612.md
text_url: https://secwatch.observer/filing/0001539497-26-001612.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/2133003/000153949726001612/0001539497-26-001612-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/2133003/000153949726001612/n5864_x17-8k.htm
generated_by_model: deepseek-v4-flash:cloud
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

VDTA

Vertical Data launches Vertical Edge, a direct-ownership edge data center platform

Vertical Data Inc. June 1, 2026, 4:47 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

XAIR

Beyond Air receives Nasdaq panel grant for continued listing; must meet bid price rule by July 31, 2026

Beyond Air, Inc. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CTOR

Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer

CITIUS ONCOLOGY, INC. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

FULC

Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review

Fulcrum Therapeutics, Inc. June 1, 2026, 4:05 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

SYRE

Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030

Spyre Therapeutics, Inc. June 1, 2026, 4:01 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001539497-26-001612

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.